Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC

It becomes the second KRAS-targeted therapy for use in patients with non –small cell lung cancer (NSCLC) whose tumors have this mutation.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news